ZHONGSHENGYAOYE(SZ:002317) Shang Hai Zheng Quan Bao·2026-02-09 19:09Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has approved the use of idle self-owned funds for entrusted wealth management, with a limit of up to RMB 400 million for a period of twelve months [2] Investment Details - The company’s wholly-owned subsidiary, Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd., has signed an agreement with Dongguan Branch of Bank of Communications to invest RMB 50 million in a structured deposit product [2] - The product is a principal-protected floating return type, with a term of 22 days and an expected annualized return rate of 1.00% to 2.10% [4][2] Risk Control Measures - The company will adhere to prudent investment principles and strictly follow the board-approved investment limits [8] - Regular market analysis and adjustments to investment strategies will be conducted to mitigate risks [8] - A detailed management system for entrusted wealth management has been established to prevent investment risks [8] Impact on the Company - The company aims to enhance the efficiency of idle funds and improve cash asset returns without affecting normal business operations [9] - Engaging in wealth management is expected to contribute positively to the overall performance of the company and benefit all shareholders [9]